Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brenda Y. Ji"'
Autor:
Eugenia Zah, Eunwoo Nam, Vinya Bhuvan, Uyen Tran, Brenda Y. Ji, Stanley B. Gosliner, Xiuli Wang, Christine E. Brown, Yvonne Y. Chen
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
One cause of relapse in cancer patients treated with chimeric antigen receptor (CAR) T cells is the loss of CAR-targeted antigens, which is particularly common in multiple myeloma (MM). Here the authors engineer a CAR recognizing two common MM-associ
Externí odkaz:
https://doaj.org/article/ec2f088f8b5544bbb62387a290932f01
Autor:
Sarah Zimmermann, Oana Diaconescu, Michiyo Yamamoto-Kawai, Brenda Y. Ji, Yun Li, Zoe O. Sandwith, Emma Van Scoy, Rubao Ji, William J. Williams, Rachel H. R. Stanley
Publikováno v:
Journal of Geophysical Research: Oceans. 124:3628-3644
Autor:
Christine E. Brown, Uyen Tran, Eugenia Zah, Eunwoo Nam, Brenda Y. Ji, Xiuli Wang, Vinya Bhuvan, Yvonne Y. Chen, Stanley B. Gosliner
Publikováno v:
Nature communications, vol 11, iss 1
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c151396e29e87f0556585ecc2e7b36
https://escholarship.org/uc/item/82q2j32v
https://escholarship.org/uc/item/82q2j32v
Autor:
Brenda Y. Ji, John M. Timmerman, Monica Mead, Jia Ming Chen, Sanaz Ghafouri, Jacqueline Trent, Christopher M. Walthers, Jacob Naparstek, Mobina Roshandell, Yvonne Y. Chen, Sarah Larson
Publikováno v:
Blood. 136:19-20
Background: Single-input anti-CD19 CAR T-cells have demonstrated clinical efficacy for relapsed or refractory (R/R) non-Hodgkin B-cell lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite excellent response rates, over 50% of CD19 CAR T-cel
Autor:
Karla K. Nawaly, Patricia A. Young, John M. Timmerman, Brenda Y. Ji, Gary J. Schiller, Monica Mead, Caitlin Harris, Christopher Walthers, Jia Ming Chen, Sanaz Ghafouri, Sven de Vos, Thomas Schweppe, Jacob Naparstek, Mobina Roshandell, Yvonne Y. Chen, Sarah Larson, Jacqueline Trent, Caspian Oliai
Publikováno v:
Cancer Research. 81:CT007-CT007
50% of patients with relapsed/refractory (R/R) B-cell lymphomas (BCL) who initially respond to CD19 CAR T therapy will relapse either due to poor CAR-T persistence or CD19 antigen escape. Preclinical data demonstrate that engineering of bispecific an
Autor:
Rachel H. R. Stanley, Evan M. Howard, Zoe O. Sandwith, Cara C. Manning, Brenda Y. Ji, David P. Nicholson
Publikováno v:
Geophysical Research Letters. 44:10-10,519